[{"orgOrder":0,"company":"Humanetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Humanetics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Humanetics \/ Inapplicable"},{"orgOrder":0,"company":"Humanetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Humanetics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Humanetics \/ Inapplicable"},{"orgOrder":0,"company":"Humanetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Humanetics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Humanetics \/ Inapplicable"},{"orgOrder":0,"company":"London Health Sciences Centre Research Institute (Lawson)","sponsor":"Greenstone Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"London Health Sciences Centre Research Institute (Lawson)","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"London Health Sciences Centre Research Institute (Lawson) \/ Greenstone Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"London Health Sciences Centre Research Institute (Lawson) \/ Greenstone Biosciences"},{"orgOrder":0,"company":"Humanetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Genistein","moa":"||Estrogen receptor beta (ESR2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Humanetics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Humanetics \/ Inapplicable"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Humanetics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Royal DSM \/ Humanetics","highestDevelopmentStatusID":"7","companyTruncated":"Royal DSM \/ Humanetics"},{"orgOrder":0,"company":"Humanetics","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Humanetics \/ Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics \/ Department of Defense"},{"orgOrder":0,"company":"Humanetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Humanetics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics \/ Inapplicable"},{"orgOrder":0,"company":"Humanetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Humanetics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics \/ Inapplicable"},{"orgOrder":0,"company":"Humanetics","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0.01,"dosageForm":"Oral Powder","sponsorNew":"Humanetics \/ US Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics \/ US Department of Defense"},{"orgOrder":0,"company":"Humanetics","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0.01,"dosageForm":"Oral Powder","sponsorNew":"Humanetics \/ US Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics \/ US Department of Defense"},{"orgOrder":0,"company":"Humanetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral","sponsorNew":"Humanetics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics \/ Inapplicable"},{"orgOrder":0,"company":"Humanetics","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Humanetics \/ Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Humanetics \/ Department of Defense"},{"orgOrder":0,"company":"Humanetics","sponsor":"National Heart, Lung, And Blood Institute","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Humanetics \/ National Heart, Lung, And Blood Institute","highestDevelopmentStatusID":"4","companyTruncated":"Humanetics \/ National Heart, Lung, And Blood Institute"},{"orgOrder":0,"company":"Humanetics","sponsor":"Regenerative Medicine Minnesota","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Oncology","graph2":"Preclinical","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Humanetics \/ Regenerative Medicine Minnesota","highestDevelopmentStatusID":"4","companyTruncated":"Humanetics \/ Regenerative Medicine Minnesota"},{"orgOrder":0,"company":"Humanetics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Humanetics \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Humanetics \/ National Institutes of Health"},{"orgOrder":0,"company":"Pharmaceutics International","sponsor":"Humanetics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pharmaceutics International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmaceutics International \/ Humanetics","highestDevelopmentStatusID":"8","companyTruncated":"Pharmaceutics International \/ Humanetics"},{"orgOrder":0,"company":"University Medical Centre Ljubljana","sponsor":"Greenstone Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"University Medical Centre Ljubljana","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medical Centre Ljubljana \/ Greenstone Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"University Medical Centre Ljubljana \/ Greenstone Biosciences"},{"orgOrder":0,"company":"Sesderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sesderma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sesderma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Sesderma \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Genistein

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : BIO 300 (genistein) is a DNA topoisomera II inhibitor administered as an oral suspension. It is being investigated for COVID-19 infection.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 22, 2025

                          Lead Product(s) : Genistein

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : The Company aims to develop its drug, BIO 300, as a medical countermeasure to reduce bodily harm caused by acute exposure to radiation.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          December 10, 2024

                          Lead Product(s) : Genistein

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase I

                          Sponsor : Department of Defense

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank

                          03

                          London Health Sciences Centre Research Institute (Lawson)

                          Country arrow
                          CPHI Shenzhen
                          Not Confirmed

                          London Health Sciences Centre Research Institute (Lawson)

                          Country arrow
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 09, 2024

                          Lead Product(s) : Genistein

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Greenstone Biosciences

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : The Funding will be used to advance the company's lead product BIO 300 (genistein), which is being evaluated in the early-stage clinical trial studies for the treatment of Acute Radiation Syndrome.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          August 08, 2024

                          Lead Product(s) : Genistein

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase I

                          Sponsor : US Department of Defense

                          Deal Size : $3.0 million

                          Deal Type : Funding

                          blank

                          05

                          University Medical Centre Ljubljana

                          Country arrow
                          CPHI Shenzhen
                          Not Confirmed

                          University Medical Centre Ljubljana

                          Country arrow
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 15, 2024

                          Lead Product(s) : Genistein

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Greenstone Biosciences

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : The funding will support a series of studies with its new drug candidate, BIO 300 (genistein), a unique, highly selective modulator of inflammation, cell cycle arrest and DNA damage repair, as a treatment for idiopathic pulmonary fibrosis.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          October 24, 2023

                          Lead Product(s) : Genistein

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Preclinical

                          Sponsor : National Heart, Lung, And Blood Institute

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank

                          07

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : The agreement aims to develop Humanetics' drug, BIO 300 (genistein), a unique, highly selective modulator of inflammation, cell cycle arrest and DNA damage repair, as a medical countermeasure to prevent bodily harm caused by acute exposure to radiation.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          June 09, 2023

                          Lead Product(s) : Genistein

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Department of Defense

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          08

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : BIO 300 (genistein) is a small molecule drug candidate which increases the killing effect of radiation on multiple tumor thus selectively protect normal tissues and to avoid protection of tumor cells. It is being developed as a treatment of inflammatory ...

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 15, 2023

                          Lead Product(s) : Genistein

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : BIO 300 (Genistein) Oral Powder is the Company’s medical countermeasure under development to prevent acute radiation syndrome (ARS). The article details results from the trial including safety, pharmacokinetics, and biomarkers in 34 healthy volunteers.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 15, 2022

                          Lead Product(s) : Genistein

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : BIO 300 Oral Powder (Genistein) is a new formulation that was developed to address unique operational needs of military personnel and first responders. It is a solid oral dosage formulation that is shelf-stable and can be self-administered.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 25, 2022

                          Lead Product(s) : Genistein

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank